Herborium Group, Inc. Completes Stock Distribution
Thursday December 21, 8:42 am ET

TEANECK, N.J.--(BUSINESS WIRE)--Herborium Group, Inc. (OTCBB: HBRM - News), a botanical therapeutics^® company that develops, licenses and markets novel botanical-based health care products and related digital support content, announced today that on December 14, 2006, it completed the distribution of shares of its common stock to the stockholders of Pacific Magtron International and Advanced Communications Technologies in connection with the September 18, 2006 merger of former Herborium, Inc. and Pacific Magtron International.

As the health care marketplace becomes more personalized with its focus on preventive medicine, it is also becoming more diversified. The sector, represented by non-traditional, natural ingredient-based health care products, is gaining both market share and professional recognition and should exceed $50 billion in the U.S. by 2007. Herborium is uniquely qualified to capitalize on this high growth opportunity. The company occupies the market space between ethical pharmaceuticals and classic nutraceuticals, and has built its strategy around product differentiation and intellectual property protection, distinguishing itself from the marketers of traditional nutraceuticals, as well as those focused on ethical pharmaceuticals and "over-the-counter" drugs.

Dr. Agnes P. Olszewski, president and CEO of Herborium, said, "To meet the needs of the new growing market, Herborium has introduced its own line of botanical therapeutics^® defined as "bridge products", an emerging category of plant-based medicinal products validated through clinical studies. Our goal is to leverage our expertise in Western and Traditional Chinese Medicine, and our novel regulatory and marketing strategies to capitalize on emerging market opportunities in the health care sector and to provide value to our stockholders."

Herborium's therapeutic candidates are based on botanical medicines that have proven effective and safe in clinical use in China. By selecting products whose efficacy and safety have been established, Herborium is able first to introduce these products to the market as premium supplements (under the DSHEA 94), and while already generating revenue, conduct confirmatory clinical testing in the U.S. in accordance with new FDA Guidance for Industry Botanical Drug Products Clinical Testing.

Herborium has attained annual revenue of $760,000-$860,000 in the last two fiscal years from sales of AcnEase^®, a product for improving conditions typically associated with Acne and Rosacea (www.acnease.com). AcnEase represents Herborium's initial product launch. In addition to dermatology, the company's priorities focus on Benign Prostate Hyperplasia (BPH), liver health, men and women's sexual health, and selected quality of life concerns including arthritis and stress management.

This release and oral statements made from time to time by the Company's representatives concerning the same subject matter may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by the Company with the SEC, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements

For more information contact:
Herborium Group, Inc.
3 Oak Street
Teaneck, New Jersey, 07666, USA
Phone: 201 836 2424